BAUSCH HEALTH COS INC (BHC) Fundamental Analysis & Valuation

NYSE:BHC • CA0717341071

5.655 USD
-0.08 (-1.31%)
Last: Mar 4, 2026, 02:42 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BHC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

BHC gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. BHC has a medium profitability rating, but doesn't score so well on its financial health evaluation. BHC is cheap, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

6

1. BHC Profitability Analysis

1.1 Basic Checks

  • BHC had positive earnings in the past year.
  • BHC had a positive operating cash flow in the past year.
  • In the past 5 years BHC reported 4 times negative net income.
  • Of the past 5 years BHC 4 years had a positive operating cash flow.
BHC Yearly Net Income VS EBIT VS OCF VS FCFBHC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B -2B -4B

1.2 Ratios

  • The Return On Assets of BHC (0.60%) is better than 79.79% of its industry peers.
  • With an excellent Return On Invested Capital value of 7.78%, BHC belongs to the best of the industry, outperforming 87.05% of the companies in the same industry.
  • BHC had an Average Return On Invested Capital over the past 3 years of 6.89%. This is significantly below the industry average of 12.91%.
  • The last Return On Invested Capital (7.78%) for BHC is above the 3 year average (6.89%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 0.6%
ROE N/A
ROIC 7.78%
ROA(3y)-0.58%
ROA(5y)-1.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)6.89%
ROIC(5y)6.18%
BHC Yearly ROA, ROE, ROICBHC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 400 600 800

1.3 Margins

  • BHC has a better Profit Margin (1.53%) than 79.79% of its industry peers.
  • The Operating Margin of BHC (21.28%) is better than 88.60% of its industry peers.
  • In the last couple of years the Operating Margin of BHC has grown nicely.
  • BHC has a better Gross Margin (70.65%) than 78.24% of its industry peers.
  • In the last couple of years the Gross Margin of BHC has remained more or less at the same level.
Industry RankSector Rank
OM 21.28%
PM (TTM) 1.53%
GM 70.65%
OM growth 3Y7.55%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.37%
BHC Yearly Profit, Operating, Gross MarginsBHC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. BHC Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BHC is creating some value.
  • BHC has more shares outstanding than it did 1 year ago.
  • BHC has more shares outstanding than it did 5 years ago.
  • BHC has a better debt/assets ratio than last year.
BHC Yearly Shares OutstandingBHC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
BHC Yearly Total Debt VS Total AssetsBHC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.2 Solvency

  • Based on the Altman-Z score of 0.29, we must say that BHC is in the distress zone and has some risk of bankruptcy.
  • BHC's Altman-Z score of 0.29 is in line compared to the rest of the industry. BHC outperforms 52.33% of its industry peers.
  • BHC has a debt to FCF ratio of 21.00. This is a negative value and a sign of low solvency as BHC would need 21.00 years to pay back of all of its debts.
  • BHC has a Debt to FCF ratio of 21.00. This is in the better half of the industry: BHC outperforms 77.20% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 21
Altman-Z 0.29
ROIC/WACC1.19
WACC6.55%
BHC Yearly LT Debt VS Equity VS FCFBHC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10B 20B

2.3 Liquidity

  • A Current Ratio of 1.47 indicates that BHC should not have too much problems paying its short term obligations.
  • The Current ratio of BHC (1.47) is worse than 70.98% of its industry peers.
  • A Quick Ratio of 1.08 indicates that BHC should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.08, BHC is not doing good in the industry: 75.65% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 1.08
BHC Yearly Current Assets VS Current LiabilitesBHC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BHC Growth Analysis

3.1 Past

  • BHC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
  • BHC shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.13% yearly.
  • BHC shows a small growth in Revenue. In the last year, the Revenue has grown by 6.66%.
  • Measured over the past years, BHC shows a small growth in Revenue. The Revenue has been growing by 5.04% on average per year.
EPS 1Y (TTM)0%
EPS 3Y6.97%
EPS 5Y-1.13%
EPS Q2Q%-4.35%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y8.11%
Revenue growth 5Y5.04%
Sales Q2Q%9.26%

3.2 Future

  • The Earnings Per Share is expected to decrease by -2.02% on average over the next years.
  • Based on estimates for the next years, BHC will show a decrease in Revenue. The Revenue will decrease by -1.38% on average per year.
EPS Next Y13.77%
EPS Next 2Y-2.55%
EPS Next 3Y-7.27%
EPS Next 5Y-2.02%
Revenue Next Year4.23%
Revenue Next 2Y2%
Revenue Next 3Y-2.31%
Revenue Next 5Y-1.38%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BHC Yearly Revenue VS EstimatesBHC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B 8B 10B
BHC Yearly EPS VS EstimatesBHC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

9

4. BHC Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 1.50 indicates a rather cheap valuation of BHC.
  • Based on the Price/Earnings ratio, BHC is valued cheaper than 99.48% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of BHC to the average of the S&P500 Index (26.83), we can say BHC is valued rather cheaply.
  • BHC is valuated cheaply with a Price/Forward Earnings ratio of 1.32.
  • 98.96% of the companies in the same industry are more expensive than BHC, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.95, BHC is valued rather cheaply.
Industry RankSector Rank
PE 1.5
Fwd PE 1.32
BHC Price Earnings VS Forward Price EarningsBHC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • 94.82% of the companies in the same industry are more expensive than BHC, based on the Enterprise Value to EBITDA ratio.
  • BHC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BHC is cheaper than 99.48% of the companies in the same industry.
Industry RankSector Rank
P/FCF 2.11
EV/EBITDA 6.39
BHC Per share dataBHC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40

4.3 Compensation for Growth

  • BHC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • BHC has a very decent profitability rating, which may justify a higher PE ratio.
  • A cheap valuation may be justified as BHC's earnings are expected to decrease with -7.27% in the coming years.
PEG (NY)0.11
PEG (5Y)N/A
EPS Next 2Y-2.55%
EPS Next 3Y-7.27%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BHC Dividend Analysis

5.1 Amount

  • BHC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BHC Fundamentals: All Metrics, Ratios and Statistics

BAUSCH HEALTH COS INC

NYSE:BHC (3/4/2026, 2:42:33 PM)

5.655

-0.08 (-1.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-20
Earnings (Next)04-28
Inst Owners45.78%
Inst Owner Change-1.85%
Ins Owners10.79%
Ins Owner Change21.29%
Market Cap2.10B
Revenue(TTM)10.27B
Net Income(TTM)157.00M
Analysts48.89
Price Target7.43 (31.39%)
Short Float %1.72%
Short Ratio2.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.64%
Min EPS beat(2)-13.87%
Max EPS beat(2)2.59%
EPS beat(4)1
Avg EPS beat(4)-10.87%
Min EPS beat(4)-25.13%
Max EPS beat(4)2.59%
EPS beat(8)3
Avg EPS beat(8)-7.33%
EPS beat(12)6
Avg EPS beat(12)-4.52%
EPS beat(16)7
Avg EPS beat(16)-7.67%
Revenue beat(2)2
Avg Revenue beat(2)1.43%
Min Revenue beat(2)0.64%
Max Revenue beat(2)2.23%
Revenue beat(4)3
Avg Revenue beat(4)0.41%
Min Revenue beat(4)-1.57%
Max Revenue beat(4)2.23%
Revenue beat(8)6
Avg Revenue beat(8)0.66%
Revenue beat(12)9
Avg Revenue beat(12)1.15%
Revenue beat(16)10
Avg Revenue beat(16)0.16%
PT rev (1m)1.04%
PT rev (3m)2.3%
EPS NQ rev (1m)16.33%
EPS NQ rev (3m)16.33%
EPS NY rev (1m)0%
EPS NY rev (3m)0.65%
Revenue NQ rev (1m)-0.25%
Revenue NQ rev (3m)-0.25%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)-0.01%
Valuation
Industry RankSector Rank
PE 1.5
Fwd PE 1.32
P/S 0.2
P/FCF 2.11
P/OCF 1.5
P/B N/A
P/tB N/A
EV/EBITDA 6.39
EPS(TTM)3.77
EY66.67%
EPS(NY)4.29
Fwd EY75.85%
FCF(TTM)2.68
FCFY47.35%
OCF(TTM)3.78
OCFY66.76%
SpS27.68
BVpS-1.49
TBVpS-44.41
PEG (NY)0.11
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.6%
ROE N/A
ROCE 9.85%
ROIC 7.78%
ROICexc 8.27%
ROICexgc 34.78%
OM 21.28%
PM (TTM) 1.53%
GM 70.65%
FCFM 9.67%
ROA(3y)-0.58%
ROA(5y)-1.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)6.89%
ROIC(5y)6.18%
ROICexc(3y)7.29%
ROICexc(5y)6.47%
ROICexgc(3y)46.04%
ROICexgc(5y)39.55%
ROCE(3y)8.72%
ROCE(5y)7.82%
ROICexgc growth 3Y6.69%
ROICexgc growth 5Y7.05%
ROICexc growth 3Y16.83%
ROICexc growth 5Y15.41%
OM growth 3Y7.55%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.37%
F-Score6
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 21
Debt/EBITDA 6.08
Cap/Depr 33.69%
Cap/Sales 3.96%
Interest Coverage 1.42
Cash Conversion 41.26%
Profit Quality 632.48%
Current Ratio 1.47
Quick Ratio 1.08
Altman-Z 0.29
F-Score6
WACC6.55%
ROIC/WACC1.19
Cap/Depr(3y)27.35%
Cap/Depr(5y)23.9%
Cap/Sales(3y)3.53%
Cap/Sales(5y)3.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y6.97%
EPS 5Y-1.13%
EPS Q2Q%-4.35%
EPS Next Y13.77%
EPS Next 2Y-2.55%
EPS Next 3Y-7.27%
EPS Next 5Y-2.02%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y8.11%
Revenue growth 5Y5.04%
Sales Q2Q%9.26%
Revenue Next Year4.23%
Revenue Next 2Y2%
Revenue Next 3Y-2.31%
Revenue Next 5Y-1.38%
EBIT growth 1Y17.85%
EBIT growth 3Y16.27%
EBIT growth 5Y10.72%
EBIT Next Year33.3%
EBIT Next 3Y-2.01%
EBIT Next 5Y1.07%
FCF growth 1Y-21%
FCF growth 3YN/A
FCF growth 5Y4.37%
OCF growth 1Y-12.34%
OCF growth 3YN/A
OCF growth 5Y4.73%

BAUSCH HEALTH COS INC / BHC FAQ

What is the ChartMill fundamental rating of BAUSCH HEALTH COS INC (BHC) stock?

ChartMill assigns a fundamental rating of 4 / 10 to BHC.


Can you provide the valuation status for BAUSCH HEALTH COS INC?

ChartMill assigns a valuation rating of 9 / 10 to BAUSCH HEALTH COS INC (BHC). This can be considered as Undervalued.


Can you provide the profitability details for BAUSCH HEALTH COS INC?

BAUSCH HEALTH COS INC (BHC) has a profitability rating of 6 / 10.


Can you provide the financial health for BHC stock?

The financial health rating of BAUSCH HEALTH COS INC (BHC) is 3 / 10.